ProQR Therapeutics NV
NASDAQ:PRQR
ProQR Therapeutics NV
Intangible Assets
ProQR Therapeutics NV
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Pharming Group NV
AEX:PHARM
|
Intangible Assets
$67.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
72%
|
||
Uniqure NV
NASDAQ:QURE
|
Intangible Assets
$76.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
70%
|
CAGR 10-Years
15%
|
||
argenx SE
XBRU:ARGX
|
Intangible Assets
$141.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
||
Merus NV
NASDAQ:MRUS
|
Intangible Assets
$1.9m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
||
LAVA Therapeutics NV
NASDAQ:LVTX
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
ProQR Therapeutics NV
Glance View
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).